Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend payer with buyback and growth plan to 2030

Hikma Pharmaceuticals PLC has raised its dividend and launched a $250 million share buyback while targeting $5 billion in revenue by 2030, drawing attention from US investors via its ADR and London listing.

Hikma Pharmaceuticals PLC has drawn renewed interest from US investors after confirming a 5% dividend increase in 2025 and announcing a $250 million share buyback, alongside a long?term ambition to grow group revenue to $5 billion by 2030, according to a recent commentary by CEO Said Darwazah published via Marketscreener on April 24, 2026.

As of May 9, 2026, Hikma’s London?listed shares (LSE: HIK) trade around 1,410 pence, implying a market capitalization of roughly £3.03 billion and a trailing?12?month price?to?earnings ratio of about 7.8, according to MarketBeat data as of May 8, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hikma Pharmaceuticals PLC
• Sector/industry: Healthcare, drug manufacturers – specialty and generic
• Headquarters/country: United Kingdom
• Core markets: North America, Middle East and North Africa, United Kingdom, Europe
• Key revenue drivers: Generic injectables, oral and respiratory generics, branded products
• Home exchange/listing venue: London Stock Exchange (HIK); ADR traded OTC in the US (HKMPY)
• Trading currency: GBP (LSE), USD (ADR)

Hikma Pharmaceuticals PLC: core business model

Hikma Pharmaceuticals PLC develops, manufactures, and markets a broad portfolio of generic, branded, and non?branded pharmaceutical products, operating through three main segments: injectables, generics, and branded, according to Morningstar’s company profile as of May 8, 2026.

The injectables segment is the largest revenue contributor, supplying generic injectable medicines to hospitals across multiple markets and supported by a network of manufacturing facilities, which helps the company maintain a relatively stable base of hospital?channel sales.

The generics segment focuses on oral, nasal, and inhalation products, including the US?focused Hikma Rx business, which generated more than $1 billion in revenue in 2025 and is positioned as the seventh?largest supplier of generic medicines in the United States, according to Darwazah’s Marketscreener commentary dated April 24, 2026.

Main revenue and product drivers for Hikma Pharmaceuticals PLC

Geographically, North America is Hikma’s key revenue?generating region, followed by the Middle East and North Africa, the United Kingdom, and other European markets, according to Morningstar’s regional breakdown as of May 8, 2026.

The company’s US oral, nasal, and inhalation generic business, Hikma Rx, has become a core growth engine, with management highlighting its steady transformation toward more complex products, an expanded respiratory and specialty portfolio, and a growing contract?manufacturing offering, which could support higher?margin sales over time.

Group revenue reached over $3.3 billion in 2025, up from about $250 million at the time of the London listing two decades ago, reflecting a long?term expansion into new geographies and therapeutic areas, according to Darwazah’s Marketscreener piece as of April 24, 2026.

Dividend, buyback, and balance?sheet strength

Hikma is positioned as a leading dividend payer in its sector, with a trailing dividend yield of about 4.37%, placing it in the top quartile of dividend?paying stocks, according to MarketBeat data as of May 8, 2026.

In 2025 the company increased its dividend by 5% and is currently executing a $250 million share buyback, while maintaining investment?grade debt ratings and a robust balance sheet, according to Darwazah’s Marketscreener commentary dated April 24, 2026.

Why Hikma Pharmaceuticals PLC matters for US investors

For US investors, Hikma is accessible via its ADR listed on the OTC market under the ticker HKMPY, which provides exposure to a diversified generic and branded pharmaceutical business with a strong footprint in North America and the Middle East.

The company’s US?focused Hikma Rx business, with more than $1 billion in 2025 revenue and a position among the top?10 generic suppliers in the country, links Hikma’s performance directly to US healthcare demand, pricing dynamics, and regulatory developments, making it relevant for investors tracking the US generics and hospital?injectables space.

Conclusion

Hikma Pharmaceuticals PLC combines a diversified generics and branded?pharma portfolio with a strong presence in North America and the Middle East, underpinned by a long?term revenue target of $5 billion by 2030 and a track record of dividend growth.

The company’s 5% dividend increase in 2025 and a $250 million share buyback, alongside investment?grade ratings and healthy cash generation, suggest a focus on returning capital to shareholders while funding growth initiatives, according to recent commentary and market data.

However, investors should remain mindful of pricing pressure in generics, regulatory scrutiny, and the cyclical nature of hospital?channel demand, which can affect margins and earnings even as the company executes its expansion plans.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.